Report on extraordinary general meeting held in NeuroSearch A/S

Announcement                                                                    


Report on extraordinary general meeting held in NeuroSearch A/S                 

Pursuant to announcement, the extraordinary general meeting of NeuroSearch A/S  
was held today Friday 21 December 2007.                                         

The suggested amendment to article 5 of the Articles of Association was finally 
adopted by the general meeting following which the board of directors' is       
authorised to increase the company's share capital in one or more issues of a   
total of nominally DKK 76,000,000 (3,800,000 shares of DKK 20 each) until 31    
December 2011.                                                                  


Asger Aamund                                                                    
Chairman of the Board                                                           



Contact person:                                                                 
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate  
Communications, telephone: +45 4460 8212 or +45 4017 5103                       



NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX
Nordic Exchange Copenhagen A/S. The company's core business covers the          
development of novel drugs, based on a broad and well-established drug discovery
platform focusing on ion channels and CNS disorders. A substantial part of the  
activities are partner financed through a broad alliance with GlaxoSmithKline   
(GSK) and collaborations with among others Abbott and Astellas. The drug        
pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in   
Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase  
III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in     
partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD   
(Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in             
schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder
and Parkinson's disease (Phase I) ABT-107 as well as ABT-560 for the treatment  
of various CNS diseases - both (Phase I) in collaboration with Abbott, NSD-644  
(Phase I) in collaboration with GSK and ACR343 in Parkinson's disease (Phase I).
In addition, NeuroSearch has a broad portfolio of preclinical drug candidates   
and holds equity interests in several biotech companies.